Last reviewed · How we verify
Retapamulin Ointment, 1%
Retapamulin Ointment, 1%, marketed by GlaxoSmithKline, holds a position in the topical antibiotic market with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from other topical antibiotics. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Retapamulin Ointment, 1% |
|---|---|
| Also known as | Retapamulin Ointment, 1% |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Treatment of Staphylococcus Aureus Colonization in Hand Eczema (NA)
- Retapamulin as a Decolonizing Agent for MRSA (PHASE3)
- Efficacy Study of Altabax to Clear Methicillin-resistant Staphylococcus Aureus (MRSA) Nasal Colonization (PHASE4)
- Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA (PHASE3)
- Treatment of Patients Colonized With Methicillin-Resistant Staphylococcus Aureus Prior to Bone and Joint Surgery (PHASE2)
- Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo (PHASE3)
- Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections. (PHASE4)
- Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Retapamulin Ointment, 1% CI brief — competitive landscape report
- Retapamulin Ointment, 1% updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI